Research News

ASH 2023: Total Lifetime Costs of Treating Chronic Lymphocytic Leukemia are High Treatment advances in chronic lymphocytic leukemia (CLL) have improved outcomes for people living with this disease. Relapses remain common, though, and people with CLL often receive multiple lines…

ASH 2023: Barriers Identified to the Use of CAR T-cell Therapy in Non-Hodgkin Lymphoma While chimeric antigen receptor (CAR) T-cell therapy represents a promising treatment option for patients with non-Hodgkin lymphoma (NHL), many community physicians face challenges that make it…

ASH 2023: MRD Status Predicts Progression-free Survival Outcomes in Follicular Lymphoma The disease course in follicular lymphoma (FL) is highly variable, and it is currently difficult to predict which patients will experience long, durable responses and who will relapse quickly…

Updates from the 2022 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 300 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific…

ASH 2022: Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy Consolidation with either whole-brain radiation therapy (WBRT) or autologous stem cell transplant (autoSCT) improves overall survival in patients with primary central nervous system lymphoma (PCNSL), regardless of first-line…

ASH 2022: Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Combination therapy with rituximab (Rituxan) and lenalidomide (Revlimid) was approved for use in relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) based on the results…